Muyuan Foods (SZ:002714) 2 1 Shi Ji Jing Ji Bao Dao·2025-11-30 00:01Core Viewpoint - Muyuan Foods Co., Ltd. has re-submitted its application for an IPO on the Hong Kong Stock Exchange after its initial submission expired, aiming for dual listing in both A-shares and H-shares [2][4]. Group 1: Company Overview - Muyuan Foods is the largest pig farming company in China and has maintained the top position globally in terms of pig production capacity and output since 2021, with a global market share of 5.6% as of 2024 [7]. - The company’s main business includes the entire pig farming industry chain, covering feed processing, breeding, and slaughtering, with the pig farming segment accounting for 98.7% of total revenue in the first half of 2025 [7]. Group 2: Financial Performance - The company's revenues for 2022, 2023, and 2024 were 124.83 billion CNY, 110.86 billion CNY, and 137.95 billion CNY, respectively, with a revenue of 76.46 billion CNY and a net profit of 10.79 billion CNY reported in the first half of 2025 [7]. - The gross profit margin improved from 7.7% in the first half of 2024 to 19.0% in the first half of 2025, primarily due to better margins in the pig farming business [7]. Group 3: Shareholding and Management - The direct controlling shareholder of Muyuan Foods is Muyuan Industrial Group Co., Ltd., holding a 15.54% stake, while the chairman, Qin Yinglin, directly holds 20.86 million shares [8]. - Qin Yinglin and his wife collectively own 54.91% of the company and were ranked 16th on the 2025 Hurun Rich List with a wealth of 187 billion CNY [10]. Group 4: Market Strategy and Future Plans - The IPO is a key step in the company's internationalization strategy, with plans to expand into emerging markets where per capita meat consumption is still low [10]. - The company intends to use the IPO proceeds to enhance its overseas market presence, strengthen R&D across the entire industry chain, and invest in breeding, smart farming, nutritional management, and biosecurity [10]. Group 5: Debt and Financial Risks - The company has shown significant changes in its debt structure, with net current liabilities reaching 15.59 billion CNY, 31.08 billion CNY, 24.16 billion CNY, and 16.64 billion CNY as of the end of 2022, 2023, 2024, and mid-2025, respectively [12]. - The company acknowledges the risk of liquidity issues due to its past net current liabilities and the potential for significant impairment losses on biological assets valued at 8.17 billion CNY and 30.22 billion CNY as of mid-2025 [12].